ArticleCancer science2020
Potential role of transforming growth factor-beta 1/Smad signaling in secondary lymphedema after cancer surgery.
Article in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Pan-Peroxisome Proliferator-Activated Receptor Agonist IVA337 Alleviates Secondary Lymphedema via Inhibiting TGFβ/SMAD2/3 Signaling Pathway.bioRxiv : the preprint server for biology · 2026Article
- Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer-Related Lymphedema.Cancer research communications · 2026Article
- Exosomes derived from ADSCs suppress the fibrosis process of derma in secondary lymphedema.Scientific reports · 2026Article
- Mechanisms and treatments of lymphedema.Frontiers in immunology · 2026Review
- Characteristics and advances in signaling pathways, cellular communication, cell junctions, and oxidative stress in lymphedema.Frontiers in cell and developmental biology · 2025Review
- Ultrasound Imaging of the Superficial and Deep Fasciae Thickness of Upper Limbs in Lymphedema Patients Versus Healthy Subjects.Diagnostics (Basel, Switzerland) · 2024Article
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).Frontiers in pharmacology · 2024Article
- Molecular pathophysiology of secondary lymphedema.Frontiers in cell and developmental biology · 2024Review
- Topical captopril: a promising treatment for secondary lymphedema.Translational research : the journal of laboratory and clinical medicine · 2023Article
- Evaluation of Circulating MicroRNAs and Adipokines in Breast Cancer Survivors with Arm Lymphedema.International journal of molecular sciences · 2022Article
- Current Understanding of Pathological Mechanisms of Lymphedema.Advances in wound care · 2022Review
- TGF-β1 mediates pathologic changes of secondary lymphedema by promoting fibrosis and inflammation.Clinical and translational medicine · 2022Article
- Integrated bioinformatics analysis identifies established and novel TGFβ1-regulated genes modulated by anti-fibrotic drugs.Scientific reports · 2022Article
- Pharmacological Treatment of Secondary Lymphedema.Frontiers in pharmacology · 2022Review
- Crosstalk Between microRNAs and the Pathological Features of Secondary Lymphedema.Frontiers in cell and developmental biology · 2021Review
- Potential role of transforming growth factor-beta 1/Smad signaling in secondary lymphedema after cancer surgery.Cancer science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 3 countries.
Funding
Abstract
Secondary lymphedema often develops after cancer surgery, and over 250 million patients suffer from this complication. A major symptom of secondary lymphedema is swelling with fibrosis, which lowers the patient's quality of life, even if cancer does not recur. Nonetheless, the pathophysiology of secondary lymphedema remains unclear, with therapeutic approaches limited to physical or surgical therapy. There is no effective pharmacological therapy for secondary lymphedema. Notably, the lack of animal models that accurately mimic human secondary lymphedema has hindered pathophysiological investigations of the disease. Here, we developed a novel rat hindlimb model of secondary lymphedema and showed that our rat model mimics human secondary lymphedema from early to late stages in terms of cell proliferation, lymphatic fluid accumulation, and skin fibrosis. Using our animal model, we investigated the disease progression and found that transforming growth factor-beta 1 (TGFB1) was produced by macrophages in the acute phase and by fibroblasts in the chronic phase of the disease. TGFB1 promoted the transition of fibroblasts into myofibroblasts and accelerated collagen synthesis, resulting in fibrosis, which further indicates that myofibroblasts and TGFB1/Smad signaling play key roles in fibrotic diseases. Furthermore, the presence of myofibroblasts in skin samples from lymphedema patients after cancer surgery emphasizes the role of these cells in promoting fibrosis. Suppression of myofibroblast-dependent TGFB1 production may therefore represent an effective pharmacological treatment for inhibiting skin fibrosis in human secondary lymphedema after cancer surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.